{"type":"trials","record":{"id":87190,"source_id":"isrctn","external_id":"ISRCTN33957677","title":"A pilot study to examine the safety and efficacy of posterior juxta-scleral (80 mg) triamcinolone acetonide, administration, in addition to Visudyne (verteporfin) photodynamic therapy for predominantly classic choroidal neovascularisation secondary to age-related macular degeneration: an open-label, randomised, active controlled trial","brief_summary":"The aim of this study is to assess the effectiveness of posterior juxtascleral triamcinolone in reducing visual loss when used in conjunction with photodynamic therapy, for the treatment ofexudative age related macular degeneration. We will be comparing the effect of the combined treatment against the standard treatment (Photodynamic Therapy [PDT]).The actions of truamcinolone are anti-inflammatory and anti-angiogenic. A beneficial effect of steroids in the eyes of patients with choroidal neovascularisation has been suggested in the literature. As of 15/02/2012, the anticipated end date of trial was updated from 15/01/2008 to 01/11/2007. The trial was terminated early in November 2007 due to poor recruitment follwing the NICE approval of Lucentis for treatment of neovascular AMD.","overall_status":"Stopped","phases":[],"study_type":"Interventional","sponsor":"King's College Hospital (UK)","enrollment":80,"countries":["United Kingdom","England"],"start_date":"2006-01-16","completion_date":"2007-11-01","last_update_date":"2012-02-15","source_url":"https://www.isrctn.com/ISRCTN33957677","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Stopped. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Adult","comparator":null,"attribution":"Source: ISRCTN ISRCTN33957677; retrieved 2026-09-25","interventions":["Triamcinolone acetonide","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["The percentage of less than 15 letter loss at one year.","1. Percentage of more than 30 letter loss at one year 2. Number of re-treatments required in one year 3. Change in lesi…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Macula degeneration","Patients are randomised to one of two treatments: 1. Patients receive Photodynamic Treatment (PDT) on their initial tre…","Triamcinolone acetonide","Drug"],"relevance_confidence":80,"source_quality_score":98,"freshness_score":35,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn33957677","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2006-01-16 to 2007-11-01","comparator":null,"confidence":"structured-source","population":"All · Adult","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.597Z","intervention":["Triamcinolone acetonide","Drug"],"participants":80,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The percentage of less than 15 letter loss at one year.","1. Percentage of more than 30 letter loss at one year 2. Number of re-treatments required in one year 3. Change in lesi…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87190","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}